Treatment of Nonmetastatic Castration Resistant Prostate Cancer

被引：1
作者：
Luo, Jia [1 ]
Beer, Tomasz M. [2 ]
Graff, Julie N. [2 ,3 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] VA Portland Hlth Care Syst, Portland, OR USA
来源：
ONCOLOGY-NEW YORK | 2016年 / 30卷 / 04期
关键词：
METASTASIS-FREE SURVIVAL; ANDROGEN-RECEPTOR GENE; ANTIANDROGEN WITHDRAWAL; PHASE-III; MEN; THERAPY; HORMONE; ENZALUTAMIDE; BICALUTAMIDE; COMBINATION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.
引用
收藏
页码：336 / 344
页数：9
相关论文
共 50 条
  • [41] Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment
    Anantharaman, Archana
    Small, Eric J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (07) : 625 - 633
  • [42] Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries
    Toledo Pereira, Felipe Moraes
    Goncalves e Silva, Adriano
    Abbade Dettino, Aldo Lourenco
    Garcia Cardoso, Ana Paula
    Sasse, Andre Deeke
    Kann, Ariel Galapo
    Dzik, Carlos
    Herchenhorn, Daniel
    Fontes Jardim, Denis Leonardo
    Lopera, Diego
    Ayadi, Mouna
    Salman, Pamela
    Manneh Kopp, Ray Antonio
    De Carvalho, Ricardo Saraiva
    De Araujo Cavallero, Sandro Roberto
    Aguiar, Sergio
    Souza, Vinicius Carrera
    Uson, Pedro Luiz Serrano, Jr.
    Soares, Andrey
    JCO GLOBAL ONCOLOGY, 2021, 7 : 545 - 549
  • [43] Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary
    Stein, Cy A.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (05) : 407 - 409
  • [44] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [45] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (05) : 558 - 567
  • [46] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
  • [47] PSMA PET-CT redefines nonmetastatic castration-resistant prostate cancer
    Ost, Piet
    NATURE REVIEWS UROLOGY, 2020, 17 (03) : 133 - 134
  • [48] New Treatment Options in Castration-Resistant Prostate Cancer
    Armstrong, Andrew J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 690 - 693
  • [49] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [50] Treatment and trials in non-metastatic castration-resistant prostate cancer
    Lokeshwar, Soum D.
    Klaassen, Zachary
    Saad, Fred
    NATURE REVIEWS UROLOGY, 2021, 18 (07) : 433 - 442
12345